XML 39 R26.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 12 Months Ended
Mar. 29, 2025
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION SEGMENT AND ENTERPRISE-WIDE INFORMATION
The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of our enterprise resource planning system, impairments and write downs, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration liability and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation.

We do not track our assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, our CODM does not review assets by segment when assessing business performance and allocating resources.
Selected information by reportable segment is presented below:
(In thousands)202520242023
Net sales
Plasma$535,431 $569,535 $499,916 
Blood Center261,124 283,231 287,034 
Hospital564,269 456,289 381,710 
Net sales by business unit$1,360,824 $1,309,055 $1,168,660 
Significant segment expenses and operating performance
Plasma
Cost of goods sold$237,050 $264,042 $254,474 
Selling, general and administrative98,418 109,729 106,006 
Research and development15,453 13,797 14,690 
Plasma operating income$184,510 $181,967 $124,746 
Blood Center
Cost of goods sold$142,512 $165,564 $144,364 
Selling, general and administrative60,023 67,339 74,024 
Research and development5,770 7,956 4,374 
Blood Center operating income$52,819 $42,372 $64,272 
Hospital
Cost of goods sold$199,499 $167,172 $147,831 
Selling, general and administrative241,760 209,680 181,368 
Research and development34,035 27,239 23,096 
Hospital operating income$88,975 $52,198 $29,415 
Corporate and unallocated expenses
Amortization of acquired assets$(63,217)$(35,378)$(32,640)
Acquisition, integration and divestiture related costs
(22,904)(11,249)411 
Restructuring and restructuring related costs(21,158)(23,588)(11,549)
Digital transformation costs(20,273)(15,667)(4,536)
Contingent Consideration23,022 — — 
Other(1)
43 (25,772)(14,086)
Operating income221,817 164,883 156,033 
Interest and other expense, net(9,746)(13,018)(14,630)
Income before provision for income taxes$212,071 $151,865 $141,403 
(1) Comprised of write downs of certain assets, MDR and IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, impairment of intangible assets, PCS2® related charges and gain on divestiture.
Net revenues by business unit are as follows:
(In thousands)202520242023
Plasma$535,431 $569,535 $499,916 
Apheresis213,134 211,173 207,618 
Whole Blood47,990 72,058 79,416 
Blood Center261,124 283,231 287,034 
Interventional Technologies255,019 174,285 126,717 
Blood Management Technologies309,250 282,004 254,993 
Hospital$564,269 $456,289 $381,710 
Total net revenues$1,360,824 $1,309,055 $1,168,660 

(In thousands)202520242023
Depreciation and amortization
Plasma$48,264 $45,712 $41,612 
Blood Center10,077 13,391 13,927 
Hospital57,245 38,112 37,768 
Total depreciation and amortization (excluding impairment charges)$115,586 $97,215 $93,307 

(In thousands)March 29,
2025		March 30,
2024
Long-lived assets(1)
Plasma$189,833 $211,121 
Blood Center40,337 54,262 
Hospital53,882 45,979 
Total long-lived assets$284,052 $311,362 
(1) Long-lived assets are comprised of property, plant and equipment.

Selected information by operating regions is presented below:
(In thousands)March 29,
2025		March 30,
2024
Long-lived assets(1)
United States$217,212 $246,473 
Japan1,250 1,597 
Europe20,024 15,310 
Rest of Asia28,705 26,728 
Other16,861 21,254 
Total long-lived assets$284,052 $311,362 
(1) Long-lived assets are comprised of property, plant and equipment.
(In thousands)202520242023
Net revenues
United States$1,010,918 $970,007 $842,897 
Japan62,408 58,087 61,295 
Europe175,655 160,142 156,680 
Rest of Asia92,305 107,536 104,135 
Other19,538 13,283 3,653 
Total net revenues$1,360,824 $1,309,055 $1,168,660